BiotechTube
Home/Pipeline/Aducanumab (Aduhelm)

Aducanumab (Aduhelm)

Alzheimer's Disease

MarketedActive (Limited)N/A

Key Facts

Indication
Alzheimer's Disease
Phase
Marketed
Status
Active (Limited)
Company
Biogen

About Biogen

Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.

View full company profile

Therapeutic Areas

NeurologyImmunologyRare Diseases

Other Alzheimer's Disease Drugs

DrugCompanyPhase
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
LecanemabBioArcticLaunched
BAN2401BioArcticPreclinical
itMSCsStemedica Cell TechnologiesClinical Development
Aucuba-001Aucuba SciencesPreclinical
ALTA Drug SeriesAlteron TherapeuticsPreclinical
NTRX-07NeuroTherapiaPhase 2
3D Neuronal Disease ModelsBioTalentumResearch
Not Publicly DisclosedCerecinPhase 1/2